Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients

  • Review Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Tacrolimus is a pivotal immunosuppressant agent used in solid-organ transplantation. It was originally formulated for oral administration as Prograf®, a twice-daily immediate-release capsule. In an attempt to improve patient adherence, retain manufacturer market share and/or reduce health care costs, newer once-daily prolonged-release formulations of tacrolimus (Advagraf® and Envarsus® XR) and various generic versions of Prograf® are becoming available. Tacrolimus has a narrow therapeutic index. Small variations in drug exposure due to formulation differences can have a significant impact on patient outcomes. The aim of this review is to critically analyse the published data on the clinical pharmacokinetics of once-daily tacrolimus in solid-organ transplant patients. Forty-three traditional (non-compartmental) and five population pharmacokinetic studies were identified and evaluated. On the basis of the stricter criteria for narrow-therapeutic-index drugs, Prograf®, Advagraf® and Envarsus® XR are not bioequivalent [in terms of the area under the concentration–time curve from 0 to 24 h (AUC0–24) or the minimum concentration (C min)]. Patients may require a daily dosage increase if converted from Prograf® to Advagraf®, while a daily dosage reduction appears necessary for conversion from Prograf® to Envarsus® XR. Prograf® itself, or generic immediate-release tacrolimus, can be administered in a once-daily regimen with a lower than double daily dose being reported to give 24-h exposure equivalent to that of a twice-daily regimen. Intense clinical and concentration monitoring is prudent in the first few months after any conversion to once-daily tacrolimus dosing; however, there is no guarantee that therapeutic drug monitoring strategies applicable to one formulation (or twice-daily dosing) will be equally applicable to another. The correlation between the tacrolimus AUC0–24 and C min is variable and not strong for all three formulations, indicating that trough measurements may not always give a good indication of overall drug exposure. Further investigation is required into whether the prolonged-release formulations have reduced within-subject pharmacokinetic variability, which would be a distinct advantage. Whether the effects of factors that influence tacrolimus absorption and pre-systemic metabolism (patient genotype status; gastrointestinal disease and disorders) and drug interactions differ across the formulations needs to be further elucidated. Most pharmacokinetic comparison studies to date have involved relatively stable patients, and many have been sponsored by the pharmaceutical companies manufacturing the new formulations. Larger randomized, controlled trials are needed in different transplant populations to determine whether there are differences in efficacy and toxicity across the formulations and whether formulation conversion is worthwhile in the longer term. While it has been suggested that once-daily administration of tacrolimus may improve patient compliance, further studies are required to demonstrate this. Mistakenly interchanging different tacrolimus formulations can lead to serious patient harm. Once-daily tacrolimus is now available as an alternative to twice-daily tacrolimus and can be used de novo in solid-organ transplant recipients or as a different formulation for existing patients, with appropriate dosage modifications. Clinicians need to be fully aware of pharmacokinetic and possible outcome differences across the different formulations of tacrolimus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. US Organ Procurement and Transplantation Network. Scientific registry of transplant recipients. 2012. http://srtr.transplant.hrsa.gov/annual_reports/2012/

  2. US Food and Drug Administration. Approved drug products with therapeutic equivalence equations (orange book). Washington, DC: US Food & Drug Administration; 2014.

    Google Scholar 

  3. Staatz C, Tett S. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43(10):623–53.

    Article  CAS  PubMed  Google Scholar 

  4. Johnston A. Equivalence and interchangeability of narrow therapeutic index drugs in organ transplantation. Eur J Hosp Pharm Sci Pract. 2013;20(5):302–7. doi:10.1136/ejhpharm-2012-000258.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Hardinger K, Park J, Schnitzler M, Koch M, Miller B, Brennan D. Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. Am J Transplant. 2004;4(4):621–5. doi:10.1111/j.1600-6143.2004.00383.x.

    Article  CAS  PubMed  Google Scholar 

  6. Heffron T, Pescovitz M, Florman S, Kalayoglu M, Emre S, Smallwood G, et al. Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients. Am J Transplant. 2007;7(6):1609–15. doi:10.1111/j.1600-6143.2007.01803.x.

    Article  CAS  PubMed  Google Scholar 

  7. Reuters. Analysis—Astellas loses patent on key drug, outlook unclear. 2008. http://uk.reuters.com/article/2008/04/08/sppage015-t145114-oishe-idUKT14511420080408. Accessed 1 Apr 2015.

  8. Therapeutic Goods Administration. Australian public assessment report for Prograf-XL. Australian Government Department of Health and Ageing, Canberra, Australia. 2010. http://www.tga.gov.au/file/1465/download. Accessed 14 Jan 2015.

  9. Wente MN, Sauer P, Mehrabi A, Weitz J, Büchler MW, Schmidt J, et al. Review of the clinical experience with a modified release form of tacrolimus [FK506E (MR4)] in transplantation. Clin Transplant. 2006;20(Suppl 17):80–4. doi:10.1111/j.1399-0012.2006.00605.x.

    Article  PubMed  Google Scholar 

  10. Chisholm M, Middleton M. Modified-release tacrolimus. Ann Pharmacother. 2006;40(2):270–5. doi:10.1345/aph.1E657.

    Article  CAS  PubMed  Google Scholar 

  11. Generics and Biosimilars Initiative. Generics applications under review—April 2014. 2014. http://www.gabionline.net/Generics/General/Generics-applications-under-review-by-EMA-April-2014. Accessed 1 Apr 2015.

  12. Gaber A, Alloway R, Bodziak K, Kaplan B, Bunnapradist S. Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. Transplantation. 2013;96(2):191–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Grinyó JM, Petruzzelli S. Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations. Expert Rev Clin Immunol. 2014;10(12):1567–79. doi:10.1586/1744666X.2014.983903.

    Article  PubMed  Google Scholar 

  14. Barraclough K, Isbel N, Johnson D, Campbell S, Staatz C. Once- versus twice-daily tacrolimus: are the formulations truly equivalent? Drugs. 2011;71(12):1561–77.

    Article  CAS  PubMed  Google Scholar 

  15. Alloway R, Steinberg S, Khalil K, Gourishankar S, Miller J, Norman D, et al. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc. 2005;37(2):867–70. doi:10.1016/j.transproceed.2004.12.222.

    Article  CAS  PubMed  Google Scholar 

  16. Cabello M, García P, González-Molina M, Díez de los Rios MJ, García-Sáiz M, Gutiérrez C, et al. Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. Transplant Proc. 2010;42(8):3038–40. doi:10.1016/j.transproceed.2010.08.008.

    Article  CAS  PubMed  Google Scholar 

  17. de Jonge H, Kuypers D, Verbeke K, Vanrenterghem Y. Reduced C-0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation. 2010;90(5):523–9. doi:10.1097/TP.0b013e3181e9feda.

    Article  PubMed  Google Scholar 

  18. Diez Ojea B, Alonso Alvarez M, Aguado Fernández S, Baños Gallardo M, García Melendreras S, Gómez Huertas E. Three-month experience with tacrolimus once-daily regimen in stable renal allografts. Transplant Proc. 2009;41(6):2323–5. doi:10.1016/j.transproceed.2009.06.048.

  19. Glowacki F, Lionet A, Hammelin J, Labalette M, Provot F, Hazzan M, et al. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients. Clin Pharmacokinet. 2011;50(7):451–9.

    Article  CAS  PubMed  Google Scholar 

  20. Hatakeyama S, Fujita T, Yoneyama T, Koie T, Hashimoto Y, Saitoh H, et al. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients. Transplant Proc. 2012;44(1):121–3. doi:10.1016/j.transproceed.2011.11.022.

    Article  CAS  PubMed  Google Scholar 

  21. Hougardy JM, Broeders N, Kianda M, Massart A, Madhoun P, Le Moine A, et al. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. Transplantation. 2011;91(5):566–9. doi:10.1097/TP.0b013e3182098ff0.

    Article  CAS  PubMed  Google Scholar 

  22. Iaria G, Sforza D, Angelico R, Toti L, de Luca L, Manuelli M, et al. Switch from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in kidney transplantation. Transplant Proc. 2011;43(4):1028–9. doi:10.1016/j.transproceed.2011.01.130.

    Article  CAS  PubMed  Google Scholar 

  23. Ma M, Kwan L, Mok M, Yap D, Tang C, Chan T. Significant reduction of tacrolimus trough level after conversion from twice daily Prograf to once daily Advagraf in Chinese renal transplant recipients with or without concomitant diltiazem treatment. Renal Fail. 2013;35(7):942–5. doi:10.3109/0886022X.2013.808134.

    Article  CAS  Google Scholar 

  24. Meçule A, Poli L, Nofroni I, Bachetoni A, Tinti F, Umbro I, et al. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors. Transplant Proc. 2010;42(4):1317–9. doi:10.1016/j.transproceed.2010.03.123.

    Article  PubMed  Google Scholar 

  25. Midtvedt K, Jenssen T, Hartmann A, Vethe NT, Bergan S, Havnes K, et al. No change in insulin sensitivity in renal transplant recipients converted from standard to once-daily prolonged release tacrolimus. Nephrol Dial Transplant. 2011;26(11):3767–72. doi:10.1093/ndt/gfr153.

    Article  CAS  PubMed  Google Scholar 

  26. Nakamura Y, Hama K, Katayama H, Soga A, Toraishi T, Yokoyama T, et al. Safety and efficacy of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Graceptor) in stable kidney transplant recipients. Transplant Proc. 2012;44(1):124–7. doi:10.1016/j.transproceed.2011.11.051.

    Article  CAS  PubMed  Google Scholar 

  27. Niioka T, Satoh S, Kagaya H, Numakura K, Inoue T, Saito M, et al. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. Transplantation. 2012;94(10):1013–9. doi:10.1097/TP.0b013e31826bc400.

    Article  CAS  PubMed  Google Scholar 

  28. Stifft F, Stolk LM, Undre N, van Hooff JP, Christiaans MH. Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation. Transplantation. 2014;97(7):775–80. doi:10.1097/01.TP.0000437561.31212.0e.

    CAS  PubMed  Google Scholar 

  29. Tsuchiya T, Ishida H, Tanabe T, Shimizu T, Honda K, Omoto K, et al. Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus. Transplantation. 2013;96(2):198–204. doi:10.1097/TP.0b013e318296c9d5.

    Article  CAS  PubMed  Google Scholar 

  30. Uchida J, Kuwabara N, Machida Y, Iwai T, Naganuma T, Kumada N, et al. Conversion of stable kidney transplant recipients from a twice-daily Prograf to a once-daily tacrolimus formulation: a short-term study on its effects on glucose metabolism. Transplant Proc. 2012;44(1):128–33. doi:10.1016/j.transproceed.2011.11.005.

    Article  CAS  PubMed  Google Scholar 

  31. van Hooff J, Van der Walt I, Kallmeyer J, Miller D, Dawood S, Moosa M, et al. Pharmacokinetics in stable kidney transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations. Ther Drug Monitor. 2012;34(1):46–52. doi:10.1097/FTD.0b013e318244a7fd.

    Article  Google Scholar 

  32. Wehland M, Bauer S, Brakemeier S, Burgwinkel P, Glander P, Kreutz R, et al. Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations. Pharmacogenet Genom. 2011;21(4):179–84. doi:10.1097/FPC.0b013e32833ea085.

    CAS  Google Scholar 

  33. Wlodarczyk Z, Squifflet JP, Ostrowski M, Rigotti P, Stefoni S, Citterio F, et al. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant. 2009;9(11):2505–13. doi:10.1111/j.1600-6143.2009.02794.x.

    Article  CAS  PubMed  Google Scholar 

  34. Wlodarczyk Z, Ostrowski M, Mourad M, Kramer B, Abramowicz D, Oppenheimer F, et al. Tacrolimus pharmacokinetics of once- versus twice-daily formulations in de novo kidney transplantation: a substudy of a randomized phase III trial. Ther Drug Monitor. 2012;34(2):143–7. doi:10.1097/FTD.0b013e31824d1620.

    Article  CAS  Google Scholar 

  35. Wu M, Cheng C, Chen C, Wu W, Cheng C, Yu D, et al. Lower variability of tacrolimus trough concentration after conversion from Prograf to Advagraf in stable kidney transplant recipients. Transplantation. 2011;92(6):648–52. doi:10.1097/TP.0b013e3182292426.

    Article  CAS  PubMed  Google Scholar 

  36. Satoh S, Niioka T, Kagaya H, Numakura K, Inoue T, Saito M, et al. Pharmacokinetic and CYP3A5 pharmacogenetic differences between once- and twice-daily tacrolimus from the first dosing day to 1 year after renal transplantation. Pharmacogenomics. 2014;15(11):1495–506. doi:10.2217/pgs.14.98.

    Article  CAS  PubMed  Google Scholar 

  37. Carcas-Sansuan A, Espinosa-Roman L, Almeida-Paulo G, Alonso-Melgar A, Garcia-Meseguer C, Fernandez-Camblor C, et al. Conversion from Prograf to Advagraf in stable paediatric renal transplant patients and 1-year follow-up. Ped Nephrol. 2014;29(1):117–23. doi:10.1007/s00467-013-2564-y.

    Article  Google Scholar 

  38. Min S, Ha J, Kang H, Ahn S, Park T, Park D, et al. Conversion of twice-daily tacrolimus to once-daily tacrolimus formulation in stable pediatric kidney transplant recipients: pharmacokinetics and efficacy. Am J Transplant. 2013;13(8):2191–7. doi:10.1111/ajt.12274.

    Article  CAS  PubMed  Google Scholar 

  39. Alloway R, Eckhoff D, Washburn W, Teperman L. Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients. Liver Transplant. 2014;20(5):564–75. doi:10.1002/lt.23844.

    Article  Google Scholar 

  40. Fischer L, Trunecka P, Gridelli B, Roy A, Vitale A, Valdivieso A, et al. Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial. Liver Transplant. 2011;17(2):167–77. doi:10.1002/lt.22211.

    Article  Google Scholar 

  41. Beckebaum S, Iacob S, Sweid D, Sotiropoulos G, Saner F, Kaiser G, et al. Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from a twice-daily tacrolimus-based regimen to once-daily tacrolimus extended-release formulation. Transpl Int. 2011;24(7):666–75. doi:10.1111/j.1432-2277.2011.01254.x.

    Article  CAS  PubMed  Google Scholar 

  42. Comuzzi C, Lorenzin D, Rossetto A, Faraci MG, Nicolini D, Garelli P, et al. Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients. Transplant Proc. 2010;42(4):1320–1. doi:10.1016/j.transproceed.2010.03.106.

    Article  CAS  PubMed  Google Scholar 

  43. Florman S, Alloway R, Kalayoglu M, Lake K, Bak T, Klein A, et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. Transplant Proc. 2005;37(2):1211–3. doi:10.1016/j.transproceed.2004.11.086.

    Article  CAS  PubMed  Google Scholar 

  44. Marin-Gomez LM, Gomez-Bravo MA, Alamo-Martinez JA, Barrera-Pulido L, Bernal Bellido C, Suárez Artacho G, et al. Evaluation of clinical safety of conversion to Advagraf therapy in liver transplant recipients: observational study. Transplant Proc. 2009;41(6):2184–6. doi:10.1016/j.transproceed.2009.06.085.

    Article  CAS  PubMed  Google Scholar 

  45. Sańko-Resmer J, Boillot O, Wolf P, Thorburn D. Renal function, efficacy and safety postconversion from twice- to once-daily tacrolimus in stable liver recipients: an open-label multicenter study. Transpl Int. 2012;25(3):283–93. doi:10.1111/j.1432-2277.2011.01412.x.

    Article  PubMed  Google Scholar 

  46. Sugawara Y, Miyata Y, Kaneko J, Tamura S, Aoki T, Sakamoto Y, et al. Once-daily tacrolimus in living donor liver transplant recipients. Biosci Trends. 2011;5(4):156–8.

    Article  CAS  PubMed  Google Scholar 

  47. Zhang Y, Chen X, Dai X, Leng X, Zhong D. Pharmacokinetics of tacrolimus converted from twice-daily formulation to once-daily formulation in Chinese stable liver transplant recipients. Acta Pharmacol Sin. 2011;32(11):1419–23. doi:10.1038/aps.2011.125.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  48. Carcas-Sansuan A, Hierro L, Almeida-Paulo G, Frauca E, Tong H, Diaz C, et al. Conversion from Prograf to Advagraf in adolescents with stable liver transplants: comparative pharmacokinetics and 1-year follow-up. Liver Transplant. 2013;19(10):1151–8. doi:10.1002/lt.23711.

    Google Scholar 

  49. Mendez A, Berastegui C, Lopez-Meseguer M, Monforte V, Bravo C, Blanco A, et al. Pharmacokinetic study of conversion from tacrolimus twice-daily to tacrolimus once-daily in stable lung transplantation. Transplantation. 2014;97(3):358–62. doi:10.1097/01.TP.0000435699.69266.66.

    CAS  PubMed  Google Scholar 

  50. Alloway R, Vanhaecke J, Yonan N, White M, Haddad H, Rabago G, et al. Pharmacokinetics in stable head transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations. J Heart Lung Transplant. 2011;30(9):1003–10. doi:10.1016/j.healun.2011.02.008.

    Article  PubMed  Google Scholar 

  51. Andrés A, Delgado-Arranz M, Morales E, Dipalma T, Polanco N, Gutierrez-Solis E, et al. Extended-release tacrolimus therapy in de novo kidney transplant recipients: single-center experience. Transplant Proc. 2010;42(8):3034–7. doi:10.1016/j.transproceed.2010.07.044.

    Article  PubMed  Google Scholar 

  52. Bunnapradist S, Ciechanowski K, West-Thielke P, Mulgaonkar S, Rostaing L, Vasudev B, et al. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. Am J Transplant. 2013;13(3):760–9. doi:10.1111/ajt.12035.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  53. Crespo M, Mir M, Marin M, Hurtado S, Estadella C, Guri X, et al. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. Transplant Proc. 2009;41(6):2115–7. doi:10.1016/j.transproceed.2009.05.014.

    Article  CAS  PubMed  Google Scholar 

  54. Ishida K, Ito S, Tsuchiya T, Imanishi Y, Deguchi T. Clinical experience with once-daily tacrolimus in de novo kidney transplant recipients from living donors in Japan: 1-year follow up. Cent Eur J Urol. 2013;66(3):344–9. doi:10.5173/ceju.2013.03.art26.

    CAS  Google Scholar 

  55. Jelassi ML, Lefeuvre S, Karras A, Moulonguet L, Billaud EM. Therapeutic drug monitoring in de novo kidney transplant receiving the modified-release once-daily tacrolimus. Transplant Proc. 2011;43(2):491–4. doi:10.1016/j.transproceed.2011.01.043.

    Article  CAS  PubMed  Google Scholar 

  56. Kitada H, Okabe Y, Nishiki T, Miura Y, Kurihara K, Terasaka S, et al. One-year follow-up of treatment with once-daily tacrolimus in de novo renal transplant. Exp Clin Transplant. 2012;10(6):561–7. doi:10.6002/ect.2012.0087.

    Article  PubMed  Google Scholar 

  57. Silva HT, Yang HC, Abouljoud M, Kuo PC, Wisemandle K, Bhattacharya P, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant. 2007;7(3):595–608. doi:10.1111/j.1600-6143.2007.01661.x.

    Article  CAS  PubMed  Google Scholar 

  58. van Boekel GA, Aarnoutse RE, Hoogtanders KE, Havenith TR, Hilbrands LB. Delayed trough level measurement with the use of prolonged-release tacrolimus. Transpl Int. 2015;28(3):314–8. doi:10.1111/tri.12499.

    Article  PubMed  Google Scholar 

  59. European Medicines Agency. Questions and answers: positions on specific questions addressed to the Pharmacokinetics Working Party. London: European Medicines Agency, 2014 Contract No.: EMA/618604/2008 Rev.10.

  60. Considine A, Tredger JM, Heneghan M, Agarwal K, Samyn M, Heaton ND, et al. Performance of modified-release tacrolimus after conversion in liver transplant patients indicates potentially favorable outcomes in selected cohorts. Liver Transpl. 2015;21(1):29–37. doi:10.1002/lt.24022.

    Article  PubMed  Google Scholar 

  61. Niioka T, Kagaya H, Miura M, Numakura K, Saito M, Inoue T, et al. Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients. Eur J Clinic Pharmacol. 2013;69(9):1659–65. doi:10.1007/s00228-013-1514-8.

    Article  CAS  Google Scholar 

  62. Benkali K, Rostaing L, Premaud A, Woillard J, Saint-Marcoux F, Urien S, et al. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin Pharmacokinet. 2010;49(10):683–92.

    Article  CAS  PubMed  Google Scholar 

  63. Woillard J, de Winter B, Kamar N, Marquet P, Rostaing L, Rousseau A. Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations—twice daily Prograf® and once daily Advagraf®. Br J Clin Pharmacol. 2011;71(3):391–402. doi:10.1111/j.1365-2125.2010.03837.x.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  64. Saint-Marcoux F, Debord J, Undre N, Rousseau A, Marquet P. Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation. Ther Drug Monit. 2010;32(2):129–35. doi:10.1097/FTD.0b013e3181cc70db.

    CAS  PubMed  Google Scholar 

  65. Saint-Marcoux F, Debord J, Parant F, Labalette M, Kamar N, Rostaing L, et al. Development and evaluation of a simulation procedure to take into account various assays for the Bayesian dose adjustment of tacrolimus. Ther Drug Monit. 2011;33(2):171–7. doi:10.1097/FTD.0b013e31820d6ef7.

    CAS  PubMed  Google Scholar 

  66. Zhao W, Fakhoury M, Baudouin V, Storme T, Maisin A, Deschenes G, et al. Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients. Eur J Clin Pharmacol. 2013;69(2):189–95. doi:10.1007/s00228-012-1330-6.

    Article  CAS  PubMed  Google Scholar 

  67. Press R, Ploeger B, den Hartigh J, van der Straaten T, van Pelt J, Danhof M, et al. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit. 2009;31(2):187–97.

    Article  CAS  PubMed  Google Scholar 

  68. Posadas Salas MA, Srinivas TR. Update on the clinical utility of once-daily tacrolimus in the management of transplantation. Drug Des Devel Ther. 2014;8:1183–94. doi:10.2147/DDDT.S55458.

  69. Adam R, Karam V, Delvart V, Trunecka P, Samuel D. Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry. Am J Transplant. 2015;15(5):1267–82.

    Article  CAS  PubMed  Google Scholar 

  70. Trunecka P, Klempnauer J, Beckstein WO, Pirenne J, Friman S. Renal function in de novo liver transplant receipients receiving different prolonged-release tacrolimus regimens—the DIAMOND study. Am J Transplant. 2015. doi:10.1111/ajt.13182 (Epub 2015 Feb 23).

    Google Scholar 

  71. Tszyrsznic W, Borowiec A, Pawlowska E, Jazwiec R, Zochowska D, Bartlomiejczyk I, et al. Two rapid ultra performance liquid chromatography/tandem mass spectrometry (UPLC/MS/MS) methods with common sample pretreatment for therapeutic drug monitoring of immunosuppressants compared to immunoassay. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;928:9–15. doi:10.1016/j.jchromb.2013.03.014.

    Article  CAS  PubMed  Google Scholar 

  72. Hétu PO, Robitaille R, Vinet B. Successful and cost-efficient replacement of immunoassays by tandem mass spectrometry for the quantification of immunosuppressants in the clinical laboratory. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;883–884:95–101. doi:10.1016/j.jchromb.2011.10.034.

    Article  PubMed  Google Scholar 

  73. Hougardy J, de Jonge H, Kuypers D, Abramowicz D. The once-daily formulation of tacrolimus: a step forward in kidney transplantation? Transplantation. 2012;93(3):241–3. doi:10.1097/TP.0b013e31823aa56e.

    Article  CAS  PubMed  Google Scholar 

  74. Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit. 2009;31(2):139–52. doi:10.1097/FTD.0b013e318198d092.

    Article  CAS  PubMed  Google Scholar 

  75. Min DI, Chen HY, Lee MK, Ashton K, Martin MF. Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients. Pharmacother. 1997;17(3):457–63.

    CAS  Google Scholar 

  76. Tsunashima D, Kawamura A, Murakami M, Sawamoto T, Undre N, Brown M, et al. Assessment of tacrolimus absorption from the human intestinal tract: open-label, randomized, 4-way crossover study. Clin Ther. 2014;36(5):748–59. doi:10.1016/j.clinthera.2014.02.021.

    Article  CAS  PubMed  Google Scholar 

  77. Thörn M, Finnström N, Lundgren S, Rane A, Lööf L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol. 2005;60(1):54–60. doi:10.1111/j.1365-2125.2005.02389.x.

    Article  PubMed Central  PubMed  Google Scholar 

  78. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther. 1997;283(3):1552–62.

    CAS  PubMed  Google Scholar 

  79. McKinnon RA, Burgess WM, Hall PM, Roberts-Thomson SJ, Gonzalez FJ, McManus ME. Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut. 1995;36(2):259–67.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  80. Hesselink D, Bouamar R, Elens L, van Schaik R, van Gelder T. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2014;53(2):123–39. doi:10.1007/s40262-013-0120-3.

    Article  CAS  PubMed  Google Scholar 

  81. Kramer B. Tacrolimus prolonged release in kidney transplantation. Exp Rev Clin Immunol. 2009;5(2):127–33. doi:10.1586/1744666X.5.2.127.

    Article  Google Scholar 

  82. Trunečka P, Boillot O, Seehofer D, Pinna AD, Fischer L, Ericzon BG, et al. Once-daily prolonged-release tacrolimus (Advagraf) versus twice-daily tacrolimus (Prograf) in liver transplantation. Am J Transplant. 2010;10(10):2313–23. doi:10.1111/j.1600-6143.2010.03255.x.

    Article  PubMed  Google Scholar 

  83. Staatz C, Goodman L, Tett S. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet. 2010;49(3):141–75.

    Article  CAS  PubMed  Google Scholar 

  84. Staatz C, Goodman L, Tett S. Effect of CYP3A and ABCB1 Single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part II. Clin Pharmacokinet. 2010;49(4):207–21.

    Article  CAS  PubMed  Google Scholar 

  85. Filler G, Vinks A, Huang S, Jevnikar A, Muirhead N. Similar MPA exposure on modified release and regular tacrolimus. Ther Drug Monit. 2014;36(3):353–7. doi:10.1097/FTD.0000000000000021.

    Article  CAS  PubMed  Google Scholar 

  86. Borra LCP, Roodnat JI, Kal JA, Mathot RAA, Weimar W, van Gelder T. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant. 2010;25(8):2757–63. doi:10.1093/ndt/gfq096.

    Article  CAS  PubMed  Google Scholar 

  87. Muduma G, Odeyemi I, Pollock RF. A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability. J Med Econ. 2014;17(7):520–6. doi:10.3111/13696998.2014.916713.

    Article  PubMed  Google Scholar 

  88. Pollock-Barziv SM, Finkelstein Y, Manlhiot C, Dipchand AI, Hebert D, Ng VL, et al. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children. Pediatr Transplant. 2010;14(8):968–75. doi:10.1111/j.1399-3046.2010.01409.x.

    Article  PubMed  Google Scholar 

  89. Crespo M, Mir M, Marin M, Hurtado S, Estadella C, Gurí X, et al. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. Transplant Proc. 2009;41(6):2115–7. doi:10.1016/j.transproceed.2009.05.014.

    Article  CAS  PubMed  Google Scholar 

  90. Hochleitner BW, Bösmüller C, Nehoda H, Frühwirt M, Simma B, Ellemunter H, et al. Increased tacrolimus levels during diarrhea. Transpl Int. 2001;14(4):230–3. doi:10.1007/s0014710140230.

    Article  CAS  PubMed  Google Scholar 

  91. Obi Y, Ichimaru N, Kato T, Kaimori J, Okumi M, Yazawa K, et al. A single daily dose enhances the adherence to immunosuppressive treatment in kidney transplant recipients: a cross-sectional study. Clin Exp Nephrol. 2013;17(2):310–5. doi:10.1007/s10157-012-0713-4.

    Article  CAS  PubMed  Google Scholar 

  92. Kuypers D, Peeters P, Sennesael J, Kianda M, Vrijens B, Kristanto P, et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation. 2013;95(2):333–40. doi:10.1097/TP.0b013e3182725532.

    Article  CAS  PubMed  Google Scholar 

  93. Muduma G, Odeyemi I, Smith-Palmer J, Pollock R. Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence. Pat Pref Adher. 2014;8:391–9. doi:10.2147/PPA.S60213.

    Google Scholar 

  94. Gaudry K. Evergreening: a common practice to protect new drugs. Nature Biotechnol. 2011;29(10):876–9. doi:10.1038/nbt.1993.

    Article  CAS  Google Scholar 

  95. First MR. First clinical experience with the new once-daily formulation of tacrolimus. Ther Drug Monit. 2008;30(2):159–66. doi:10.1097/FTD.0b013e318167909a.

    Article  CAS  PubMed  Google Scholar 

  96. Prograf and Advagraf mix-up. Can J Hosp Pharm. 2009;62(5):417–8.

Download references

Compliance with Ethical Standards

No funding was received for the preparation of this review.

Christine Staatz and Susan Tett have no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. School of Pharmacy, The University of Queensland, Brisbane, QLD, 4072, Australia

    Christine E. Staatz & Susan E. Tett

Authors
  1. Christine E. Staatz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan E. Tett
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan E. Tett.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Staatz, C.E., Tett, S.E. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients. Clin Pharmacokinet 54, 993–1025 (2015). https://doi.org/10.1007/s40262-015-0282-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-015-0282-2

Keywords

Search

Navigation